MAGEC2 and prostate carcinoma: MAGE-C2, with the observed 7.4-fold upregulation in SBS1 ccRCCs, is a cancer cell-specific regulator of TRIM28, and its high expression is associated with poor survival in various malignancies, including bladder and prostate carcinomas; however, the role of MAGE-C2 has not yet been evaluated in RCCs [39], [40], [41], [42].